The evolution of Drugs to Watch
Powered by Cortellis Competitive Intelligence
What is Drugs to Watch?
For over a decade, The Drugs to Watch report from Clarivate has spotlighted therapies set to reach blockbuster status ($1bn+ in annual sales), reshape treatment paradigms, and meet critical unmet needs.
Powered by Cortellis Competitive Intelligence and 160+ expert analysts, it combines real-world pipeline data with predictive analytics. With 12+ years of proven accuracy, including 12 of 13 validated predictions in 2024, the report is trusted by leading pharma, biotech, and investment teams worldwide.
New Ebook: Where are they now? – The 2024 follow-up report
We tracked each 2024 Drug to Watch to see what happened next.
Did it launch? Did it gain approval? Is it meeting commercial expectations?
Download all 5 reports in one click
Look back on 5 years of forecasting innovation
2025 Edition
A new wave of breakthrough therapies—GLP-1s, bispecifics, ADCs, radiopharmaceuticals—finally reach the market after years of R&D.
2024 Edition
13 game-changing drugs spotlighted. 12 already tracking as expected. One of our most accurate forecasts yet. Check out where they are now: New eBook
2023 Edition
Focused on biosimilars, personalized medicine, and regional dynamics in China—plus sustainability in drug development.
2022 Edition
Seven high-impact, late-stage treatments identified. Also covered: regulatory shifts and the rise of generics.
2021 Edition
Innovation thrived despite the pandemic. This edition featured COVID-19 breakthroughs and milestone therapies across key diseases.
